In response to the FDA guidance document for Babesia, CTS will implement the licensed Grifols Babesia test for samples received on April 20, 2020 at the Charlotte, Dallas, Phoenix, St. Louis and Tampa laboratories. Be watching for details on an upcoming webinar that will provide you with an overview of implementing this testing.
Check out the Communication page for the complete details by clicking the link: Communications
After a recent reevaluation of the Monolisa anti-HBs EIA package insert, the CTS QA/Scientific team ...
CTS Dallas and Phoenix Labs successfully implemented WNV NAT testing on the Panther Testing Platform...
We sincerely hope to see you at this year’s AABB Annual Meeting in Boston, MA on October 12-16...
That’s just one of the reasons that National Blood Donor Month, which has taken place each Jan...
On April 29, 2019, CTS will begin performing Donor-Screen HLA® Class I and II testing on the Str...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...